Nagashree Seetharamu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3967416/publications.pdf

Version: 2024-02-01

1478505 1058476 24 242 6 citations h-index g-index papers

24 24 24 369 docs citations times ranked citing authors all docs

14

#	Article	IF	CITATIONS
1	Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics. Molecular Medicine, 2018, 24, 50.	4.4	112
2	Osimertinib in EGFR-Mutated Lung Cancer: A Review of the Existing and Emerging Clinical Data. OncoTargets and Therapy, 2021, Volume 14, 4579-4597.	2.0	21
3	Pretreatment nutritional status and response to checkpoint inhibitors in lung cancer. Lung Cancer Management, 2020, 9, LMT31.	1.5	19
4	A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non–Small Cell Lung Cancer. Clinical Cancer Research, 2021, 27, 3630-3640.	7.0	11
5	Stereotactic body radiotherapy as primary treatment for elderly and medically inoperable patients with head and neck cancer. Head and Neck, 2020, 42, 2880-2886.	2.0	10
6	Lorlatinib induced proteinuria: A case report. Journal of Oncology Pharmacy Practice, 2021, 27, 1037-1039.	0.9	8
7	An Atypical Presentation of Lichen Planus-Like Reaction from Pembrolizumab. Case Reports in Dermatological Medicine, 2019, 2019, 1-5.	0.3	7
8	Treatment of atypical pulmonary carcinoid with combination ipilimumab and nivolumab. BMJ Case Reports, 2019, 12, e231029.	0.5	7
9	Management of the neck after definitive chemoradiation in patients with HPV-associated oropharyngeal cancer: An institutional experience. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2019, 40, 684-690.	1.3	6
10	Forming the Hematology-Oncology Collaborative Videoconferencing (CO-VID) Learning Initiative: Experiential Lessons Learned From a Novel Trainee-Led Multidisciplinary Virtual Learning Platform. JCO Oncology Practice, 2022, 18, e36-e46.	2.9	6
11	Impact of stereotactic body radiation therapy on geriatric assessment and management for older patients with head and neck cancer using G8. Journal of Geriatric Oncology, 2021, 12, 122-127.	1.0	5
12	Disparities in lung cancer screening rates among the Hispanic/LatinX population. Lung Cancer Management, 2021, 10, LMT51.	1.5	5
13	<p>A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their Toxicity</p> . Lung Cancer: Targets and Therapy, 2020, Volume 11, 73-103.	2.7	4
14	Complete response with anti-PD-L1 antibody following progression on anti-PD-1 antibody in advanced non-small cell lung cancer. BMJ Case Reports, 2020, 13, e236101.	0.5	4
15	Simple parameters to solve a complex issue: predicting response to checkpoint inhibitor therapy in lung cancer. Lung Cancer Management, 2021, 10, LMT44.	1.5	3
16	Malignant struma ovarii with late recurrence harbouring high microsatellite instability. BMJ Case Reports, 2021, 14, e242081.	0.5	3
17	Improving postâ€'CRT neck assessment in patients with HPVâ€'associated OPSCC (Review). Molecular and Clinical Oncology, 2020, 13, 24.	1.0	3
18	Impact of Family and Social Network on Tobacco Cessation Amongst Cancer Patients. Cancer Control, 2021, 28, 107327482110566.	1.8	3

#	Article	IF	CITATIONS
19	Impact of Tyrosine Kinase Inhibitor Starting Dose on Outcomes in Patients With Non-Small Cell Lung Cancer. Journal of Pharmacy Practice, 2021, 34, 11-16.	1.0	2
20	Clinical efficacy with dabrafenib and trametinib in a T599_V600insT poorly differentiated metastatic thyroid carcinoma. BMJ Case Reports, 2021, 14, e243264.	0.5	1
21	Renal insufficiency in patients on PARP inhibitors: Case-based review of possible mechanisms and management. Journal of Onco-Nephrology, 2021, 5, 8-12.	0.6	1
22	Lung cancer screening guidelines are clear butÂare they being followed?. Lung Cancer Management, 2020, 9, LMT35.	1.5	1
23	Disparities in Lung Cancer Screening in Puerto Rico: A United States Colony with Unequal Benefits. Cancer Control, 2021, 28, 107327482110519.	1.8	O
24	The Evolving Role of PD-L1 Inhibition in Non-Small Cell Lung Cancer: A Review of Durvalumab and Avelumab, 2022, 5, 31-45.		0